Avalo Therapeutics
AVTX
Insidertransaktionen und Aktienkurs 2024-2026
Alle Insidertrades bei Avalo Therapeutics
| Datum |
Typ |
Insider |
Position |
Ø-Preis |
Volumen |
|
16.9.2026
|
Verkauf |
Sullivan, Christopher Ryan |
Chief Financial Officer |
16,3 $ |
202.437 $ |
|
10.9.2026
|
Verkauf |
Sullivan, Christopher Ryan |
Chief Financial Officer |
17,6 $ |
179.457 $ |
|
28.8.2026
|
Verkauf |
Doyle, Mittie |
Chief Medical Officer |
20,0 $ |
13.580 $ |
|
18.8.2026
|
Verkauf |
Sullivan, Christopher Ryan |
Chief Financial Officer |
20,1 $ |
622.324 $ |
|
17.8.2026
|
Verkauf |
Sullivan, Christopher Ryan |
Chief Financial Officer |
19,9 $ |
828.095 $ |
|
17.8.2026
|
Verkauf |
Doyle, Mittie |
Chief Medical Officer |
20,0 $ |
20.000 $ |
|
11.8.2026
|
Verkauf |
Riley, Jennifer |
Chief Strategy Officer |
19,6 $ |
52.012 $ |
|
10.8.2026
|
Verkauf |
Doyle, Mittie |
Chief Medical Officer |
20,0 $ |
13.580 $ |
|
27.7.2026
|
Verkauf |
Doyle, Mittie |
Chief Medical Officer |
20,0 $ |
20.000 $ |
|
30.6.2026
|
Verkauf |
Doyle, Mittie |
Chief Medical Officer |
20,0 $ |
93.080 $ |
|
23.6.2026
|
Verkauf |
Doyle, Mittie |
Chief Medical Officer |
18,0 $ |
26.100 $ |
|
28.5.2026
|
Verkauf |
Doyle, Mittie |
Chief Medical Officer |
16,0 $ |
10.864 $ |
|
15.5.2026
|
Verkauf |
Doyle, Mittie |
Chief Medical Officer |
18,8 $ |
56.280 $ |
|
7.5.2026
|
Verkauf |
Sullivan, Christopher Ryan |
Chief Financial Officer |
24,1 $ |
448.818 $ |
|
6.5.2026
|
Verkauf |
Varki, Paul |
Chief Legal Officer |
21,3 $ |
1.513.673 $ |
|
6.5.2026
|
Verkauf |
Chan, Mitchell |
Aufsichtsrat |
22,9 $ |
72.461 $ |
|
6.5.2026
|
Verkauf |
Sullivan, Christopher Ryan |
Chief Financial Officer |
20,5 $ |
948.721 $ |
|
6.5.2026
|
Verkauf |
Doyle, Mittie |
Chief Medical Officer |
20,8 $ |
2.203.502 $ |
|
5.5.2026
|
Verkauf |
Doyle, Mittie |
Chief Medical Officer |
16,0 $ |
26.864 $ |
|
30.4.2026
|
Verkauf |
Sullivan, Christopher Ryan |
Chief Financial Officer |
13,2 $ |
111.853 $ |
|
29.4.2026
|
Verkauf |
Sullivan, Christopher Ryan |
Chief Financial Officer |
13,1 $ |
110.736 $ |
|
6.4.2026
|
Verkauf |
Doyle, Mittie |
Chief Medical Officer |
18,0 $ |
71.508 $ |
|
2.4.2026
|
Verkauf |
Sullivan, Christopher Ryan |
Chief Financial Officer |
17,3 $ |
136.823 $ |
|
1.4.2026
|
Verkauf |
Sullivan, Christopher Ryan |
Chief Financial Officer |
16,3 $ |
133.770 $ |
|
1.4.2026
|
Verkauf |
Doyle, Mittie |
Chief Medical Officer |
16,0 $ |
10.864 $ |
|
16.3.2026
|
Verkauf |
Doyle, Mittie |
Chief Medical Officer |
16,1 $ |
411.607 $ |
|
14.11.2025
|
Verkauf |
Goldman, Jonathan |
Aufsichtsrat |
14,3 $ |
162.937 $ |
|
13.11.2024
|
Kauf |
Almenoff, June Sherie |
Aufsichtsrat |
13,0 $ |
6.500 $ |
|
12.11.2024
|
Kauf |
Almenoff, June Sherie |
Aufsichtsrat |
12,5 $ |
6.250 $ |
Alle Angaben ohne Gewähr! Keine Empfehlung/Beratung! © U.S. Securities and Exchange Commission (SEC)
Kostenlose Updates per Mail
Bestätige noch deine Email-Adresse